211 Users Online
Immune Checkpoint Inhibitors Market Segmented By Lung Cancer, Melanoma, Squamous Cell Carcinoma, Urothelial Carcinoma, Blood cancer as Therapeutic with PD-1, PD-L1, CTLA-4 Drugs
1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. PMR Analysis and Recommendations
1.4. Wheel of Fortune
2. Market Introduction
2.1. Market Definition
2.2. Market Taxonomy
3. Immune Checkpoint Inhibitors Market Opportunity Analysis
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
4. Market Background
4.1. List of Manufacturers
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Trends
5. Key Inclusions
5.1. Global Pharmaceutical Industry Outlook
5.2. Supply Chain
5.3. Pipeline Analysis
5.4. Reimbursement Scenario
5.5. Key Participants Market Presence and Regulatory Approvals, By Region
6. North America Immune Checkpoint Inhibitors Market Analysis 2013–2017 and Forecast 2018–2026
6.1. Introduction
6.2. Historical Market Size (US$ Mn) Trend Analysis by Country, 2013–2017
6.2.1. U.S.
6.2.2. Canada
6.3. Market Size (US$ Mn) Forecast By Country, 2018–2026
6.4. Historical Market Size (US$ Mn) Trend Analysis by Drug Class, 2013–2017
6.4.1. PD-1
6.4.2. PD-L1
6.4.3. CTLA-4
6.5. Market Size (US$ Mn) Forecast By Drug Class, 2018–2026
6.6. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Application, 2013–2017
6.6.1. Lung Cancer
6.6.2. Melanoma
6.6.3. Urothelial Carcinoma
6.6.4. Squamous Cell Carcinoma
6.6.5. Blood Cancer
6.6.6. Other Cancers
6.7. Market Size (US$ Mn) Forecast By Therapeutic Application, 2018–2026
6.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2017
6.8.1. Hospital Pharmacies
6.8.2. Retail Pharmacies
6.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2026
6.10. Market Attractiveness Analysis
6.10.1. By Country
6.10.2. By Drug Class
6.10.3. By Therapeutic Application
6.10.4. By Distribution Channel
6.11. Drivers and Restraints – Impact Analysis
7. Latin America Immune Checkpoint Inhibitors Market Analysis 2013–2017 and Forecast 2018–2026
7.1. Introduction
7.2. Historical Market Size (US$ Mn) Trend Analysis by Country, 2013–2017
7.2.1. Argentina
7.2.2. Brazil
7.2.3. Mexico
7.2.4. Rest of Latin America
7.3. Market Size (US$ Mn) Forecast By Country, 2018–2026
7.4. Historical Market Size (US$ Mn) Trend Analysis by Drug Class, 2013–2017
7.4.1. PD-1
7.4.2. PD-L1
7.4.3. CTLA-4
7.5. Market Size (US$ Mn) Forecast By Drug Class, 2018–2026
7.6. Historical Market Size (US$ Mn) Trend Analysis by Therapeutic Application, 2013–2017
7.6.1. Lung Cancer
7.6.2. Melanoma
7.6.3. Urothelial Carcinoma
7.6.4. Squamous Cell Carcinoma
7.6.5. Blood Cancer
7.6.6. Other Cancers
7.7. Market Size (US$ Mn) Forecast By Therapeutic Application, 2018–2026
7.8. Historical Market Size (US$ Mn) Trend Analysis by Distribution Channel, 2013–2017
7.8.1. Hospital Pharmacies
7.8.2. Retail Pharmacies
7.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2026
7.10. Market Attractiveness Analysis
7.10.1. By Country
7.10.2. By Drug Class
7.10.3. By Therapeutic Application
7.10.4. By Distribution Channel
7.11. Drivers and Restraints – Impact Analysis
8. Europe Immune Checkpoint Inhibitors Market Analysis 2013–2017 and Forecast 2018–2026
8.1. Introduction
8.2. Historical Market Size (US$ Mn) Trend Analysis by Country, 2013–2017
8.2.1. Germany
8.2.2. U.K.
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Russia
8.2.7. Rest of Europe
8.3. Market Size (US$ Mn) Forecast By Country, 2018–2026
8.4. Historical Market Size (US$ Mn) Trend Analysis by Drug Class, 2013–2017
8.4.1. PD-1
8.4.2. PD-L1
8.4.3. CTLA-4
8.5. Market Size (US$ Mn) Forecast By Drug Class, 2018–2026
8.6. Historical Market Size (US$ Mn) Trend Analysis by Therapeutic Application, 2013–2017
8.6.1. Lung Cancer
8.6.2. Melanoma
8.6.3. Urothelial Carcinoma
8.6.4. Squamous Cell Carcinoma
8.6.5. Blood Cancer
8.6.6. Other Cancers
8.7. Market Size (US$ Mn) Forecast By Therapeutic Application, 2018–2026
8.8. Historical Market Size (US$ Mn) Trend Analysis by Distribution Channel, 2013–2017
8.8.1. Hospital Pharmacies
8.8.2. Retail Pharmacies
8.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2026
8.10. Market Attractiveness Analysis
8.10.1. By Country
8.10.2. By Drug Class
8.10.3. By Therapeutic Application
8.10.4. By Distribution Channel
8.11. Drivers and Restraints – Impact Analysis
9. Asia Pacific Immune Checkpoint Inhibitors Market Analysis 2013–2017 and Forecast 2018–2026
9.1. Introduction
9.2. Historical Market Size (US$ Mn) Trend Analysis by Country, 2013–2017
9.2.1. China
9.2.2. India
9.2.3. Australia and New Zealand
9.2.4. ASEAN
9.2.5. Rest of Asia Pacific
9.3. Market Size (US$ Mn) Forecast By Country, 2018–2026
9.4. Historical Market Size (US$ Mn) Trend Analysis by Drug Class, 2013–2017
9.4.1. PD-1
9.4.2. PD-L1
9.4.3. CTLA-4
9.5. Market Size (US$ Mn) Forecast By Drug Class, 2018–2026
9.6. Historical Market Size (US$ Mn) Trend Analysis by Therapeutic Application, 2013–2017
9.6.1. Lung Cancer
9.6.2. Melanoma
9.6.3. Urothelial Carcinoma
9.6.4. Squamous Cell Carcinoma
9.6.5. Blood Cancer
9.6.6. Other Cancers
9.7. Market Size (US$ Mn) Forecast By Therapeutic Application, 2018–2026
9.8. Historical Market Size (US$ Mn) Trend Analysis by Distribution Channel, 2013–2017
9.8.1. Hospital Pharmacies
9.8.2. Retail Pharmacies
9.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2026
9.10. Market Attractiveness Analysis
9.10.1. By Country
9.10.2. By Drug Class
9.10.3. By Therapeutic Application
9.10.4. By Distribution Channel
9.11. Drivers and Restraints – Impact Analysis
10. Japan Immune Checkpoint Inhibitors Market Analysis 2013–2017 and Forecast 2018–2026
10.1. Introduction
10.2. Historical Market Size (US$ Mn) Trend Analysis by Drug Class, 2013–2017
10.2.1. PD-1
10.2.2. PD-L1
10.2.3. CTLA-4
10.3. Market Size (US$ Mn) Forecast By Drug Class, 2018–2026
10.4. Historical Market Size (US$ Mn) Trend Analysis by Therapeutic Application, 2013–2017
10.4.1. Lung Cancer
10.4.2. Melanoma
10.4.3. Urothelial Carcinoma
10.4.4. Squamous Cell Carcinoma
10.4.5. Blood Cancer
10.4.6. Other Cancers
10.5. Market Size (US$ Mn) Forecast By Therapeutic Application, 2018–2026
10.6. Historical Market Size (US$ Mn) Trend Analysis by Distribution Channel, 2013–2017
10.6.1. Hospital Pharmacies
10.6.2. Retail Pharmacies
10.7. Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2026
10.8. Market Attractiveness Analysis
10.8.1. By Country
10.8.2. By Drug Class
10.8.3. By Therapeutic Application
10.8.4. By Distribution Channel
10.9. Drivers and Restraints – Impact Analysis
11. Middle East & Africa Immune Checkpoint Inhibitors Market Analysis 2013–2017 and Forecast 2018–2026
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Trend Analysis by Country, 2013–2017
11.2.1. GCC Countries
11.2.2. South Africa
11.2.3. Rest of MEA
11.3. Market Size (US$ Mn) Forecast By Country, 2018–2026
11.4. Historical Market Size (US$ Mn) Trend Analysis by Drug Class, 2013–2017
11.4.1. PD-1
11.4.2. PD-L1
11.4.3. CTLA-4
11.5. Market Size (US$ Mn) Forecast By Drug Class, 2018–2026
11.6. Historical Market Size (US$ Mn) Trend Analysis by Therapeutic Application, 2013–2017
11.6.1. Lung Cancer
11.6.2. Melanoma
11.6.3. Urothelial Carcinoma
11.6.4. Squamous Cell Carcinoma
11.6.5. Blood Cancer
11.6.6. Other Cancers
11.7. Market Size (US$ Mn) Forecast By Therapeutic Application, 2018–2026
11.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2017
11.8.1. Hospital Pharmacies
11.8.2. Retail Pharmacies
11.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2026
11.10. Market Attractiveness Analysis
11.10.1. By Country
11.10.2. By Drug Class
11.10.3. By Therapeutic Application
11.10.4. By Distribution Channel
11.11. Drivers and Restraints – Impact Analysis
12. Forecast Factors: Relevance and Impact
13. Forecast Assumptions
14. Market Structure Analysis
14.1. Market Structure by Tier of Companies
14.2. Market Share Analysis (2017) for Top Players
14.3. Key Development Analysis of Top Players
15. Competition Analysis
15.1. Competition Dashboard
15.2. Company Deep Dive
15.2.1. AstraZeneca Plc.
15.2.1.1. Overview
15.2.1.2. Sales Footprint
15.2.1.3. Strategy
15.2.2. Bristol-Myers Squibb Co.
15.2.2.1. Overview
15.2.2.2. Sales Footprint
15.2.2.3. Strategy
15.2.3. Roche Holding AG
15.2.3.1. Overview
15.2.3.2. Sales Footprint
15.2.3.3. Strategy
15.2.4. Incyte Corporation
15.2.4.1. Overview
15.2.4.2. Sales Footprint
15.2.4.3. Strategy
15.2.5. Merck & Co., Inc.
15.2.5.1. Overview
15.2.5.2. Sales Footprint
15.2.5.3. Strategy
15.2.6. Merck KGaA
15.2.6.1. Overview
15.2.6.2. Sales Footprint
15.2.6.3. Strategy
15.2.7. Sanofi
15.2.7.1. Overview
15.2.7.2. Sales Footprint
15.2.7.3. Strategy
15.2.8. Novartis AG
15.2.8.1. Overview
15.2.8.2. Sales Footprint
15.2.8.3. Strategy
16. Global Immune Checkpoint Inhibitors Market Analysis 2013–2017 and Forecast 2018–2026, By Region
16.1. Introduction/Key Findings
16.2. Historical Market Size (US$ Mn) Trend Analysis by Region, 2013–2017
16.3. Market Size (US$ Mn) Forecast By Region, 2018–2026
16.3.1. North America
16.3.2. Latin America
16.3.3. Europe
16.3.4. Asia Pacific
16.3.5. China
16.3.6. Middle East & Africa
16.4. Market Attractiveness Analysis by Region
17. Global Immune Checkpoint Inhibitors Analysis 2013–2017 and Forecast 2018–2026, By Drug Class
17.1. Introduction/Key Findings
17.2. Historical Market Size (US$ Mn) Trend Analysis by Drug Class, 2013–2017
17.2.1. PD-1
17.2.2. PD-L1
17.2.3. CTLA-4
17.3. Market Size (US$ Mn) Forecast By Drug Class, 2018–2026
17.4. Market Attractiveness Analysis by Drug Class
18. Global Immune Checkpoint Inhibitors Market Analysis 2013–2017 and Forecast 2018–2026, By Therapeutic Application
18.1. Introduction/Key Findings
18.2. Historical Market Size (US$ Mn) Trend Analysis by Therapeutic Application, 2013–2017
18.2.1. Lung Cancer
18.2.2. Melanoma
18.2.3. Urothelial Carcinoma
18.2.4. Squamous Cell Carcinoma
18.2.5. Blood Cancer
18.2.6. Other Cancers
18.3. Others Market Size (US$ Mn) Forecast By Therapeutic Application, 2018–2026
18.4. Market Attractiveness Analysis by Therapeutic Application
19. Global Immune Checkpoint Inhibitors Market Analysis 2013–2017 and Forecast 2018–2026, By Distribution Channel
19.1. Introduction/Key Findings
19.2. Historical Market Size (US$ Mn) Trend Analysis by Distribution Channel, 2013–2017
19.2.1. Hospital Pharmacies
19.2.2. Retail Pharmacies
19.3. Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2026
19.4. Market Attractiveness Analysis by Distribution Channel
20. Global Immune Checkpoint Inhibitors Market Analysis 2013–2017 and Forecast 2018–2026
20.1. Market Value Share Analysis by All Segment
20.2. Y-o-Y Growth Analysis by All Segment
20.3. Absolute $ Opportunity
21. Research Methodology
FREE Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
Table 01: List of Key Immune Checkpoint Inhibitor Manufacturers
Table 02: Number of FDA Approvals (2010-2017)
Table 03: Bristol-Myers Squib Immune Checkpoint Inhibitors Pipeline
Table 04: AstraZeneca Immune Checkpoint Inhibitors Pipeline
Table 05: Roche Holdings AG Immune Checkpoint Inhibitors Pipeline
Table 06: Merck KgaA Immune Checkpoint Inhibitors Pipeline
Table 07: Others Immune Checkpoint Inhibitors Pipeline
Table 08: North America Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 09: North America Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
Table 10: North America Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Therapeutic Application
Table 11: North America Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
Table 12: Latin America Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 13: Latin America Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
Table 14: Latin America Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Therapeutic Application
Table 15: Latin America Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
Table 16: Europe Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 17: Europe Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
Table 18: Europe Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Therapeutic Application
Table 19: Europe Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
Table 20: APEJ Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 21: APEJ Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
Table 22: Europe Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Therapeutic Application
Table 23: APEJ Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
Table 24: Japan Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
Table 25: Japan Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Therapeutic Application
Table 26: Japan Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channe6
Table 27: MEA Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 28: APEJ Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
Table 29: MEA Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Therapeutic Application
Table 30: MEA Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
Table 31: Global Immune Checkpoint Inhibitors Market size (US$ Mn) Analysis 2013–2016 and Forecast 2017–2026, By Region
Table 32: Global Immune Checkpoint Inhibitors Market size (US$ Mn) Analysis 2013–2016 and Forecast 2017–2026, By Drug Class
Table 33: Global Immune Checkpoint Inhibitors Market size (US$ Mn) Analysis 2013–2016 and Forecast 2017–2026, By Therapeutic Applications
Table 34: Global Immune Checkpoint Inhibitors Market size (US$ Mn) Analysis 2013–2016 and Forecast 2017–2026, By Distribution Channel
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version
Figure 01: Immune Checkpoint Inhibitor Market Share By Drug Class (2017)
Figure 02: Immune Checkpoint Inhibitor Market Share By Therapeutic Application (2017)
Figure 03: Immune Checkpoint Inhibitor Market Share By Distribution Channel (2017)
Figure 04: Immune Checkpoint Inhibitor Market Share By Region (2017)
Figure 05: Global Immune Checkpoint Inhibitor Market Value (US$ Mn) Forecast 2018 and 2026
Figure 06: Global Healthcare Expenditure in US$ Tn (2013–2020)
Figure 07: Expenditure on Health, (% of GDP), by Country, 2016 - 2021
Figure 08: Number of FDA approved pharmaceuticals (2010-2017)
Figure 09: Pipeline Analysis Based on Company (2017)
Figure 10: Pipeline Analysis Based on Phase (2017)
Figure 11: Pipeline Analysis Based on API (2017)
Figure 12: Pipeline Analysis Based on Target (2017)
Figure 13: Pipeline Analysis Based on Therapeutic Area (2017)
Figure 14: Bristol-Myers Squib Pipeline Analysis Based on Therapeutic Indication (2017)
Figure 15: Bristol-Myers Squib Pipeline Analysis Based on Phase (2017)
Figure 16: Bristol-Myers Squib Pipeline Analysis Based on API (2017)
Figure 17: Bristol-Myers Squib Pipeline Analysis Based on Target (2017)
Figure 18: AstraZeneca Pipeline Analysis Based on Therapeutic Indication (2017)
Figure 19: AstraZeneca Pipeline Analysis Based on Phase (2017)
Figure 20: AstraZeneca Pipeline Analysis Based on API (2017)
Figure 21: AstraZeneca Pipeline Analysis Based on Target (2017)
Figure 22: Pipeline Analysis Based on Phase (2017)
Figure 23: Pipeline Analysis Based on Therapeutic Indication (2017)
Figure 24: Pipeline Analysis Based on Phase (2017)
Figure 25: Pipeline Analysis Based on Therapeutic Indication (2017)
Figure 26: Pipeline Analysis Based on Therapeutic Indication (2017)
Figure 27: Pipeline Analysis Based on Phase (2017)
Figure 28: Pipeline Analysis Based on API (2017)
Figure 29: Pipeline Analysis Based on Target (2017)
Figure 30: North America Immune Checkpoint Inhibitors Market Size (US$ Mn), 2018–2026
Figure 31: North America Immune Checkpoint Inhibitors Market Y-o-Y Growth (%), 2018–2026, by Country
Figure 32: U.S. Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 33: Canada Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 34: North America PD-1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 35: North America PD-L1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 36: North America CTLA-4 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 37: North America Lung Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 38: North America Melanoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 39: North America Squamous Cell Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 40: North America Urothelial Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 41: North America Blood Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 42: North America Other Cancers Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 43: Hospital Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 44: Retail Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 45: North America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Country
Figure 46: North America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Drug Class
Figure 47: North America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Therapeutic Application
Figure 48: North America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Distribution Channel
Figure 49: Latin America Immune Checkpoint Inhibitors Market Size (US$ Mn), 2018–2026
Figure 50: Latin America Immune Checkpoint Inhibitors Market Y-o-Y Growth (%), 2018–2026, by Country
Figure 51: Brazil Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 52: Mexico Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 53: Rest of Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 54: Latin America PD-1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 55: Latin America PD-L1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 56: Latin America CTLA-4 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 57: Latin America Lung Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 58: Latin America Melanoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 59: Latin America Squamous Cell Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 60: Latin America Urothelial Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 61: Latin America Blood Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 62: Latin America Other Cancers Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 63: Hospital Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 64: Retail Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 65: Latin America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Country
Figure 66: Latin America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Drug Class
Figure 67: Latin America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Therapeutic Application
Figure 68: Latin America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Distribution Channel
Figure 69: Europe Immune Checkpoint Inhibitors Market Size (US$ Mn), 2018–2026
Figure 70: Europe Immune Checkpoint Inhibitors Market Y-o-Y Growth (%), 2018–2026, by Country
Figure 71: U.K. Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 72: Germany Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 73: Russia Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 74: France Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 75: Italy Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 76: Spain Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 77: Rest of Europe Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 78: Europe PD-1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 79: Europe PD-L1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 80: Europe CTLA-4 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 81: Europe Lung Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 82: Europe Melanoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 83: Europe Squamous Cell Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 84: Europe Urothelial Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 85: Europe Blood Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 86: Europe Other Cancers Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 87: Hospital Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 88: Retail Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 89: Europe Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Country
Figure 90: Europe Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Drug Class
Figure 91: Europe Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Therapeutic Application
Figure 92: Europe Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Distribution Channel
Figure 93: APEJ Immune Checkpoint Inhibitors Market Size (US$ Mn), 2018–2026
Figure 94: APEJ Immune Checkpoint Inhibitors Market Y-o-Y Growth (%), 2018–2026, by Country
Figure 95: India Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 96: China Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 97: Australia & New Zealand Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 98: ASEAN Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 99: Rest of APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 100: APEJ PD-1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 101: APEJ PD-L1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 102: APEJ CTLA-4 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 103: APEJ Lung Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 104: APEJ Melanoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 105: APEJ Squamous Cell Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 106: APEJ Urothelial Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 107: APEJ Blood Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 108: APEJ Other Cancers Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 109: Hospital Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 110: Retail Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 111: APEJ Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Country
Figure 112: APEJ Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Drug Class
Figure 113: APEJ Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Therapeutic Application
Figure 114: APEJ Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Distribution Channel
Figure 115: Japan Immune Checkpoint Inhibitors Market Size (US$ Mn), 2018–2026
Figure 116: Japan PD-1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 117: Japan PD-L1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 118: Japan CTLA-4 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 119: Japan Lung Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 120: Japan Melanoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 121: Japan Squamous Cell Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 122: Japan Urothelial Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 123: Japan Blood Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 124: Japan Other Cancers Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 125: Hospital Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 126: Retail Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 127: Japan Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Drug Class
Figure 128: Japan Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Therapeutic Application
Figure 129: Japan Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Distribution Channel
Figure 130: MEA Immune Checkpoint Inhibitors Market Size (US$ Mn), 2018–2026
Figure 131: MEA Immune Checkpoint Inhibitors Market Y-o-Y Growth (%), 2018–2026, by Country
Figure 132: GCC Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 133: South Africa Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 134: Rest of MEA Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 135: MEA PD-1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 136: MEA PD-L1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 137: MEA CTLA-4 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 138: MEA Lung Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 139: MEA Melanoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 140: MEA Squamous Cell Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 141: MEA Urothelial Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 142: MEA Blood Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 143: MEA Other Cancers Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 144: Hospital Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 145: Retail Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 146: MEA Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Country
Figure 147: MEA Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Drug Class
Figure 148: MEA Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Therapeutic Application
Figure 149: MEA Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Distribution Channel
Figure 150: Key Developments, By type of Development
Figure 151: Key Developments, By Year
Figure 152: Key Developments, By Company
Figure 153: Key Development Snapshot, by Type of Development
Figure 154: Global Immune Checkpoint Inhibitors Market Share Analysis (%) By Region, 2018 & 2026
Figure 155: Global Immune Checkpoint Inhibitors Market Y-o-Y Growth (%) By Region, 2018–2026
Figure 156: Global Immune Checkpoint Inhibitors Market Attractiveness Analysis By Region, 2018–2026
Figure 157: Global Immune Checkpoint Inhibitors Market Share Analysis (%) By Drug Class, 2018 & 2026
Figure 158: Global Immune Checkpoint Inhibitors Market Y-o-Y Growth (%) By Drug Class, 2018–2026
Figure 159: Global Immune Checkpoint Inhibitors Market Attractiveness Analysis By Drug Class, 2018–2026
Figure 160: Global Immune Checkpoint Inhibitors Market Share Analysis (%) By Therapeutic Application, 2018 & 2026
Figure 161: Global Immune Checkpoint Inhibitors Market Y-o-Y Growth (%) By Therapeutic Application, 2018–2026
Figure 162: Global Immune Checkpoint Inhibitors Market Attractiveness Analysis By Therapeutic Application, 2018–2026
Figure 163: Global Immune Checkpoint Inhibitors Market Share Analysis (%) By Distribution Channel, 2018 & 2026
Figure 164: Global Immune Checkpoint Inhibitors Market Y-o-Y Growth (%) By Distribution Channel, 2018–2026
Figure 165: Global Immune Checkpoint Inhibitors Market Attractiveness Analysis By Distribution Channel, 2018–2026
Figure 166: Global Immune Checkpoint Inhibitors Market Value Analysis and Forecast, 2016–2025 (US$ Mn)
Figure 167: Global Immune Checkpoint Inhibitors Market Value (US$ Mn), 2013–2017
Figure 168: Global Immune Checkpoint Inhibitors Market Absolute $ Opportunity (US$ Mn), 2017–2026
